Last reviewed · How we verify
Propionyl-L-carnitine Tablets — Competitive Intelligence Brief
phase 3
carnitine derivative
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Propionyl-L-carnitine Tablets (Propionyl-L-carnitine Tablets) — Lee's Pharmaceutical Limited. Propionyl-L-carnitine is a carnitine derivative that may improve blood flow and reduce oxidative stress.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Propionyl-L-carnitine Tablets TARGET | Propionyl-L-carnitine Tablets | Lee's Pharmaceutical Limited | phase 3 | carnitine derivative |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (carnitine derivative class)
- Lee's Pharmaceutical Limited · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Propionyl-L-carnitine Tablets CI watch — RSS
- Propionyl-L-carnitine Tablets CI watch — Atom
- Propionyl-L-carnitine Tablets CI watch — JSON
- Propionyl-L-carnitine Tablets alone — RSS
- Whole carnitine derivative class — RSS
Cite this brief
Drug Landscape (2026). Propionyl-L-carnitine Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/propionyl-l-carnitine-tablets. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab